Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 268

1.

Direct conversion of human fibroblast to hepatocytes using a single inducible polycistronic vector.

Ballester M, Bolonio M, Santamaria R, Castell JV, Ribes-Koninckx C, Bort R.

Stem Cell Res Ther. 2019 Nov 4;10(1):317. doi: 10.1186/s13287-019-1416-5.

2.

A Physiology-Based Model of Human Bile Acid Metabolism for Predicting Bile Acid Tissue Levels After Drug Administration in Healthy Subjects and BRIC Type 2 Patients.

Baier V, Cordes H, Thiel C, Castell JV, Neumann UP, Blank LM, Kuepfer L.

Front Physiol. 2019 Sep 27;10:1192. doi: 10.3389/fphys.2019.01192. eCollection 2019.

3.

A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.

Petrov PD, García-Mediavilla MV, Guzmán C, Porras D, Nistal E, Martínez-Flórez S, Castell JV, González-Gallego J, Sánchez-Campos S, Jover R.

Mol Nutr Food Res. 2019 Oct;63(20):e1900487. doi: 10.1002/mnfr.201900487. Epub 2019 Jul 30.

PMID:
31322321
4.

Monitoring of system conditioning after blank injections in untargeted UPLC-MS metabolomic analysis.

Martínez-Sena T, Luongo G, Sanjuan-Herráez D, Castell JV, Vento M, Quintás G, Kuligowski J.

Sci Rep. 2019 Jul 8;9(1):9822. doi: 10.1038/s41598-019-46371-w.

5.

Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations.

Albrecht W, Kappenberg F, Brecklinghaus T, Stoeber R, Marchan R, Zhang M, Ebbert K, Kirschner H, Grinberg M, Leist M, Moritz W, Cadenas C, Ghallab A, Reinders J, Vartak N, van Thriel C, Golka K, Tolosa L, Castell JV, Damm G, Seehofer D, Lampen A, Braeuning A, Buhrke T, Behr AC, Oberemm A, Gu X, Kittana N, van de Water B, Kreiling R, Fayyaz S, van Aerts L, Smedsrød B, Ellinger-Ziegelbauer H, Steger-Hartmann T, Gundert-Remy U, Zeigerer A, Ullrich A, Runge D, Lee SML, Schiergens TS, Kuepfer L, Aguayo-Orozco A, Sachinidis A, Edlund K, Gardner I, Rahnenführer J, Hengstler JG.

Arch Toxicol. 2019 Jun;93(6):1609-1637. doi: 10.1007/s00204-019-02492-9. Epub 2019 Jun 27.

PMID:
31250071
6.

A novel microRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients.

López-Riera M, Conde I, Castell JV, Jover R.

Toxicol Sci. 2018 Jun 14. pii: kfz138. doi: 10.1093/toxsci/kfz138. [Epub ahead of print]

PMID:
31198949
7.

Hepatocyte transplantation, a step forward?

Ott M, Castell JV.

J Hepatol. 2019 Jun;70(6):1049-1050. doi: 10.1016/j.jhep.2019.03.022. Epub 2019 Apr 17. No abstract available.

PMID:
31005337
8.

Long-term and mechanistic evaluation of drug-induced liver injury in Upcyte human hepatocytes.

Tolosa L, Jiménez N, Pelechá M, Castell JV, Gómez-Lechón MJ, Donato MT.

Arch Toxicol. 2019 Feb;93(2):519-532. doi: 10.1007/s00204-018-2349-y. Epub 2018 Nov 13.

PMID:
30426164
9.

Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes.

Gu X, Albrecht W, Edlund K, Kappenberg F, Rahnenführer J, Leist M, Moritz W, Godoy P, Cadenas C, Marchan R, Brecklinghaus T, Pardo LT, Castell JV, Gardner I, Han B, Hengstler JG, Stoeber R.

Arch Toxicol. 2018 Dec;92(12):3505-3515. doi: 10.1007/s00204-018-2302-0. Epub 2018 Oct 13.

PMID:
30317417
10.

Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis.

García-Monzón C, Petrov PD, Rey E, Marañón P, Del Pozo-Maroto E, Guzmán C, Rodríguez de Cía J, Casado-Collado AJ, Vargas-Castrillón J, Saez A, Miquilena-Colina ME, Lo Iacono O, Castell JV, González-Rodríguez Á, Jover R.

Am J Pathol. 2018 Dec;188(12):2800-2810. doi: 10.1016/j.ajpath.2018.07.028. Epub 2018 Sep 22.

PMID:
30248338
11.

Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers.

López-Riera M, Conde I, Quintas G, Pedrola L, Zaragoza Á, Perez-Rojas J, Salcedo M, Benlloch S, Castell JV, Jover R.

Sci Rep. 2018 Jul 13;8(1):10606. doi: 10.1038/s41598-018-28854-4.

12.

Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems.

Fernández-Murga ML, Petrov PD, Conde I, Castell JV, Goméz-Lechón MJ, Jover R.

Food Chem Toxicol. 2018 Oct;120:196-212. doi: 10.1016/j.fct.2018.07.017. Epub 2018 Jul 7. Review.

PMID:
29990576
13.

Bladder cancer recurrence surveillance by urine metabolomics analysis.

Loras A, Trassierra M, Sanjuan-Herráez D, Martínez-Bisbal MC, Castell JV, Quintás G, Ruiz-Cerdá JL.

Sci Rep. 2018 Jun 15;8(1):9172. doi: 10.1038/s41598-018-27538-3.

14.

Predicting drug-induced cholestasis: preclinical models.

Petrov PD, Fernández-Murga ML, López-Riera M, Goméz-Lechón MJ, Castell JV, Jover R.

Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):721-738. doi: 10.1080/17425255.2018.1487399. Epub 2018 Jun 20. Review.

PMID:
29888962
15.

Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.

Tolosa L, Jiménez N, Pérez G, Castell JV, Gómez-Lechón MJ, Donato MT.

Arch Toxicol. 2018 Jan;92(1):383-399. doi: 10.1007/s00204-017-2036-4. Epub 2017 Jul 31.

16.

Sperm whale long-range echolocation sounds revealed by ANTARES, a deep-sea neutrino telescope.

André M, Caballé A, van der Schaar M, Solsona A, Houégnigan L, Zaugg S, Sánchez AM, Castell JV, Solé M, Vila F, Djokic D, Adrián-Martínez S, Albert A, Anghinolfi M, Anton G, Ardid M, Aubert JJ, Avgitas T, Baret B, Barrios-Martí J, Basa S, Bertin V, Biagi S, Bormuth R, Bouwhuis MC, Bruijn R, Brunner J, Busto J, Capone A, Caramete L, Carr J, Celli S, Chiarusi T, Circella M, Coleiro A, Coniglione R, Costantini H, Coyle P, Creusot A, Deschamps A, De Bonis G, Distefano C, Di Palma I, Donzaud C, Dornic D, Drouhin D, Eberl T, El Bojaddaini I, Elsässer D, Enzenhöfer A, Fehn K, Felis I, Fusco LA, Galatà S, Gay P, Geißelsöder S, Geyer K, Giordano V, Gleixner A, Glotin H, Gracia-Ruiz R, Graf K, Hallmann S, van Haren H, Heijboer AJ, Hello Y, Hernandez-Rey JJ, Hößl J, Hofestädt J, Hugon C, Illuminati G, James CW, de Jong M, Jongen M, Kadler M, Kalekin O, Katz U, Kießling D, Kouchner A, Kreter M, Kreykenbohm I, Kulikovskiy V, Lachaud C, Lahmann R, Lefèvre D, Leonora E, Loucatos S, Marcelin M, Margiotta A, Marinelli A, Martínez-Mora JA, Mathieu A, Melis K, Michael T, Migliozzi P, Moussa A, Mueller C, Nezri E, Păvălaş GE, Pellegrino C, Perrina C, Piattelli P, Popa V, Pradier T, Racca C, Riccobene G, Roensch K, Saldaña M, Samtleben DF, Sanguineti M, Sapienza P, Schnabel J, Schüssler F, Seitz T, Sieger C, Spurio M, Stolarczyk T, Sánchez-Losa A, Taiuti M, Trovato A, Tselengidou M, Turpin D, Tönnis C, Vallage B, Vallée C, Van Elewyck V, Vivolo D, Wagner S, Wilms J, Zornoza JD, Zuñiga J.

Sci Rep. 2017 Apr 12;7:45517. doi: 10.1038/srep45517.

17.

New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease.

López-Riera M, Conde I, Tolosa L, Zaragoza Á, Castell JV, Gómez-Lechón MJ, Jover R.

Front Pharmacol. 2017 Jan 25;8:3. doi: 10.3389/fphar.2017.00003. eCollection 2017.

18.

Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to develop new predictive biomarkers for early drug development.

Donato MT, López-Riera M, Castell JV, Gómez-Lechón MJ, Jover R.

Toxicol Lett. 2016 Nov 30;263:58-67. doi: 10.1016/j.toxlet.2016.10.008. Epub 2016 Oct 17.

PMID:
27765674
19.

Silencing of hepatic fate-conversion factors induce tumorigenesis in reprogrammed hepatic progenitor-like cells.

Serrano F, García-Bravo M, Blazquez M, Torres J, Castell JV, Segovia JC, Bort R.

Stem Cell Res Ther. 2016 Jul 27;7(1):96. doi: 10.1186/s13287-016-0349-5.

20.

A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury.

García-Cañaveras JC, Castell JV, Donato MT, Lahoz A.

Sci Rep. 2016 Jun 6;6:27239. doi: 10.1038/srep27239.

21.

Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing.

Tolosa L, Gómez-Lechón MJ, López S, Guzmán C, Castell JV, Donato MT, Jover R.

Toxicol Sci. 2016 Jul;152(1):214-29. doi: 10.1093/toxsci/kfw078. Epub 2016 May 4.

PMID:
27208088
22.

Model-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.

Thiel C, Cordes H, Conde I, Castell JV, Blank LM, Kuepfer L.

Arch Toxicol. 2017 Feb;91(2):865-883. doi: 10.1007/s00204-016-1723-x. Epub 2016 May 9.

23.

Hepatocyte transplantation program: Lessons learned and future strategies.

Ibars EP, Cortes M, Tolosa L, Gómez-Lechón MJ, López S, Castell JV, Mir J.

World J Gastroenterol. 2016 Jan 14;22(2):874-86. doi: 10.3748/wjg.v22.i2.874. Review.

24.

Extending metabolome coverage for untargeted metabolite profiling of adherent cultured hepatic cells.

García-Cañaveras JC, López S, Castell JV, Donato MT, Lahoz A.

Anal Bioanal Chem. 2016 Feb;408(4):1217-30. doi: 10.1007/s00216-015-9227-8. Epub 2016 Jan 14.

PMID:
26769129
25.

Transplantation of hESC-derived hepatocytes protects mice from liver injury.

Tolosa L, Caron J, Hannoun Z, Antoni M, López S, Burks D, Castell JV, Weber A, Gomez-Lechon MJ, Dubart-Kupperschmitt A.

Stem Cell Res Ther. 2015 Dec 12;6:246. doi: 10.1186/s13287-015-0227-6.

26.

Contribution to the Understanding of Particle Motion Perception in Marine Invertebrates.

André M, Kaifu K, Solé M, van der Schaar M, Akamatsu T, Balastegui A, Sánchez AM, Castell JV.

Adv Exp Med Biol. 2016;875:47-55. doi: 10.1007/978-1-4939-2981-8_6.

PMID:
26610943
27.

LC-MS untargeted metabolomic analysis of drug-induced hepatotoxicity in HepG2 cells.

García-Cañaveras JC, Jiménez N, Gómez-Lechón MJ, Castell JV, Donato MT, Lahoz A.

Electrophoresis. 2015 Sep;36(18):2294-2302. doi: 10.1002/elps.201500095. Epub 2015 Jul 22.

PMID:
26031481
28.

Human neonatal hepatocyte transplantation induces long-term rescue of unconjugated hyperbilirubinemia in the Gunn rat.

Tolosa L, López S, Pareja E, Donato MT, Myara A, Nguyen TH, Castell JV, Gómez-Lechón MJ.

Liver Transpl. 2015 Jun;21(6):801-11. doi: 10.1002/lt.24121.

29.

Repression of the nuclear receptor small heterodimer partner by steatotic drugs and in advanced nonalcoholic fatty liver disease.

Benet M, Guzmán C, Pisonero-Vaquero S, García-Mediavilla MV, Sánchez-Campos S, Martínez-Chantar ML, Donato MT, Castell JV, Jover R.

Mol Pharmacol. 2015 Apr;87(4):582-94. doi: 10.1124/mol.114.096313. Epub 2015 Jan 9.

PMID:
25576488
30.

Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex.

Marfil V, Blazquez M, Serrano F, Castell JV, Bort R.

Oncogene. 2015 Jun 4;34(23):3011-22. doi: 10.1038/onc.2014.240. Epub 2014 Sep 15.

PMID:
25220416
31.

A score model for the continuous grading of early allograft dysfunction severity.

Pareja E, Cortes M, Hervás D, Mir J, Valdivieso A, Castell JV, Lahoz A.

Liver Transpl. 2015 Jan;21(1):38-46. doi: 10.1002/lt.23990. Epub 2014 Nov 24.

32.

High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins.

Tolosa L, Carmona A, Castell JV, Gómez-Lechón MJ, Donato MT.

Arch Toxicol. 2015 Oct;89(10):1847-60. doi: 10.1007/s00204-014-1334-3. Epub 2014 Aug 27.

PMID:
25160661
33.

Interindividual variation in response to xenobiotic exposure established in precision-cut human liver slices.

Jetten MJ, Claessen SM, Dejong CH, Lahoz A, Castell JV, van Delft JH, Kleinjans JC.

Toxicology. 2014 Sep 2;323:61-9. doi: 10.1016/j.tox.2014.06.007. Epub 2014 Jun 17.

PMID:
24949552
34.

Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction.

Cortes M, Pareja E, García-Cañaveras JC, Donato MT, Montero S, Mir J, Castell JV, Lahoz A.

J Hepatol. 2014 Sep;61(3):564-74. doi: 10.1016/j.jhep.2014.04.023. Epub 2014 May 2.

PMID:
24798621
35.

A simple transcriptomic signature able to predict drug-induced hepatic steatosis.

Benet M, Moya M, Donato MT, Lahoz A, Hervás D, Guzmán C, Gómez-Lechón MJ, Castell JV, Jover R.

Arch Toxicol. 2014 Apr;88(4):967-82. doi: 10.1007/s00204-014-1197-7. Epub 2014 Jan 28.

PMID:
24469900
36.

[Liver cell therapy in the treatment of inborn errors of metabolism in children].

Pareja E, Ribes C, Gómez-Lechón MJ, Cortes M, Vila JJ, Dalmau J, Ibáñez V, Polo B, Castell JV, Mir J.

An Pediatr (Barc). 2013 Dec;79(6):390.e1-8. doi: 10.1016/j.anpedi.2013.05.018. Epub 2013 Jul 27. Review. Spanish.

37.

Neonatal livers: a source for the isolation of good-performing hepatocytes for cell transplantation.

Tolosa L, Pareja-Ibars E, Donato MT, Cortés M, López S, Jiménez N, Mir J, Castell JV, Gómez-Lechón MJ.

Cell Transplant. 2014;23(10):1229-42. doi: 10.3727/096368913X669743. Epub 2013 Jun 25.

PMID:
23803290
38.

Human hepatocyte transplantation in patients with hepatic failure awaiting a graft.

Pareja E, Gomez-Lechon MJ, Cortes M, Bonora-Centelles A, Castell JV, Mir J.

Eur Surg Res. 2013;50(3-4):273-81. doi: 10.1159/000351332. Epub 2013 Jun 18.

PMID:
23796722
39.

Multiparametric evaluation of the cytoprotective effect of the Mangifera indica L. stem bark extract and mangiferin in HepG2 cells.

Tolosa L, Rodeiro I, Donato MT, Herrera JA, Delgado R, Castell JV, Gómez-Lechón MJ.

J Pharm Pharmacol. 2013 Jul;65(7):1073-82. doi: 10.1111/jphp.12071. Epub 2013 Apr 26.

PMID:
23738735
40.

A combination of transcriptomics and metabolomics uncovers enhanced bile acid biosynthesis in HepG2 cells expressing CCAAT/enhancer-binding protein β (C/EBPβ), hepatocyte nuclear factor 4α (HNF4α), and constitutive androstane receptor (CAR).

Blazquez M, Carretero A, Ellis JK, Athersuch TJ, Cavill R, Ebbels TM, Keun HC, Castell JV, Lahoz A, Bort R.

J Proteome Res. 2013 Jun 7;12(6):2732-41. doi: 10.1021/pr400085n. Epub 2013 May 15.

PMID:
23641669
41.

HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.

Tolosa L, Gómez-Lechón MJ, Pérez-Cataldo G, Castell JV, Donato MT.

Arch Toxicol. 2013 Jun;87(6):1115-27. doi: 10.1007/s00204-013-1012-x. Epub 2013 Feb 9.

PMID:
23397584
42.

Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: a quantitative method for oxidative stress assessment of nanoparticle-treated cells.

Aranda A, Sequedo L, Tolosa L, Quintas G, Burello E, Castell JV, Gombau L.

Toxicol In Vitro. 2013 Mar;27(2):954-63. doi: 10.1016/j.tiv.2013.01.016. Epub 2013 Jan 26.

PMID:
23357416
43.

The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease.

Guzmán C, Benet M, Pisonero-Vaquero S, Moya M, García-Mediavilla MV, Martínez-Chantar ML, González-Gallego J, Castell JV, Sánchez-Campos S, Jover R.

Biochim Biophys Acta. 2013 Apr;1831(4):803-18. doi: 10.1016/j.bbalip.2012.12.014. Epub 2013 Jan 12.

PMID:
23318274
44.

Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases.

Ribes-Koninckx C, Ibars EP, Calzado Agrasot MÁ, Bonora-Centelles A, Miquel BP, Vila Carbó JJ, Aliaga ED, Pallardó JM, Gómez-Lechón MJ, Castell JV.

Cell Transplant. 2012;21(10):2267-82. doi: 10.3727/096368912X637505.

PMID:
23231960
45.

Gata4 blocks somatic cell reprogramming by directly repressing Nanog.

Serrano F, Calatayud CF, Blazquez M, Torres J, Castell JV, Bort R.

Stem Cells. 2013 Jan;31(1):71-82. doi: 10.1002/stem.1272.

46.

An in vitro tool to assess cytochrome P450 drug biotransformation-dependent cytotoxicity in engineered HepG2 cells generated by using adenoviral vectors.

Lahoz A, Vilà MR, Fabre M, Miquel JM, Rivas M, Maines J, Castell JV, Gómez-Lechón MJ.

Toxicol In Vitro. 2013 Jun;27(4):1410-5. doi: 10.1016/j.tiv.2012.08.001. Epub 2012 Aug 13.

PMID:
22910125
47.

Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method.

García-Cañaveras JC, Donato MT, Castell JV, Lahoz A.

J Lipid Res. 2012 Oct;53(10):2231-41. doi: 10.1194/jlr.D028803. Epub 2012 Jul 19.

48.

Mangifera indica L. extract and mangiferin modulate cytochrome P450 and UDP-glucuronosyltransferase enzymes in primary cultures of human hepatocytes.

Rodeiro I, José Gómez-Lechón M, Perez G, Hernandez I, Herrera JA, Delgado R, Castell JV, Teresa Donato M.

Phytother Res. 2013 May;27(5):745-52. doi: 10.1002/ptr.4782. Epub 2012 Jul 20.

PMID:
22815239
49.

Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs.

Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O'Connor JE, Gómez-Lechón MJ.

Toxicol Sci. 2012 May;127(1):187-98. doi: 10.1093/toxsci/kfs083. Epub 2012 Feb 13.

PMID:
22331495
50.

Real-time monitoring of noise in cetacean acoustic niches.

André M, van der Schaar M, Zaugg S, Houégnigan L, Sánchez A, Mas A, Castell JV.

Adv Exp Med Biol. 2012;730:593-6. doi: 10.1007/978-1-4419-7311-5_134. No abstract available.

PMID:
22278571

Supplemental Content

Loading ...
Support Center